November 21, 2024 05:30 PM ESTUpdated 06:13 PM
R&D
Cell/Gene Tx

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Jared Whitlock

Features Editor

A fe­male Rett syn­drome pa­tient died Wednes­day af­ter re­ceiv­ing Neu­ro­gene’s gene ther­a­py in a clin­i­cal tri­al, the com­pa­ny dis­closed in a new

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times